The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...